Lenalidomide in the treatment of chronic lymphocytic leukemia |
| |
| Authors: | Gentile Massimo Recchia Anna Grazia Vigna Ernesto Mazzone Carla Lucia Eugenio Gigliotti Vincenzo Bossio Sabrina Madeo Antonio Morabito Lucio Servillo Pasquale Franzese Stefania Caruso Nadia De Stefano Laura Bisconte Maria Grazia Gentile Carlo Morabito Fortunato |
| |
| Affiliation: | Unità Operativa Complessa di Ematologia, Dipartimento di Oncoematologia, Azienda Ospedaliera di Cosenza, Viale della Repubblica, 87100 Cosenza, Italy. massim.gentile@tiscali.it |
| |
| Abstract: | INTRODUCTION: insights into the role of the tumor microenvironment and of immune dysfunction in chronic lymphocytic leukemia (CLL) have opened the way for further augmenting the therapeutic armamentarium for CLL patients. In this respect, lenalidomide represents an exciting drug since it is able to eliminate CLL cells without immunosuppression. AREAS COVERED: mechanism of action and clinical trials of lenalidomide in CLL, and suggestions for its future utilization are reviewed. The most relevant papers and the meeting abstracts published up to July 2010 were used as sources for this review. This review will help readers understand the mechanism of action of lenalidomide and will provide a comprehensive summary regarding efficacy and safety of this drug in CLL patients. EXPERT OPINION: lenalidomide shows good activity against CLL. However, the toxicity profile is significant and can result in serious and potentially life-threatening side effects. Definitive data from ongoing trials will aid better definition of its status in CLL therapy. Moreover, clarification of the exact mechanism(s) of action in CLL will allow more precise use of lenalidomide and design of more efficacious combination therapies. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
